Table 2.
Changes of clinical and laboratory findings after treatment
| Dapagliflozin (n = 18) | Controls (n = 18) | Difference | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Posttreatment | P-vaule | Baseline | Posttreatment | P-vaule | Mean | P-vaule | |
| BMI (kg/m2) | 28.17 ± 1.21 | 25.92 ± 0.92 | 0.000 | 28.04 ± 1.19 | 27.04 ± 1.11 | 0.000 | −1.21 ± 0.85 | 0.004 |
| FPG (mmol/L) | 8.24 ± 0.29 | 6.56 ± 0.38 | 0.000 | 8.12 ± 0.47 | 6.53 ± 0.32 | 0.000 | 0.02 ± 0.28 | 0.850 |
| PPG (mmol/L) | 14.86 ± 1.58 | 9.95 ± 1.62 | 0.000 | 14.76 ± 1.63 | 10.23 ± 0.95 | 0.000 | −0.21 ± 1.40 | 0.563 |
| HbA1c (%) | 8.38 ± 0.95 | 6.49 ± 0.71 | 0.000 | 8.45 ± 1.10 | 6.35 ± 0.36 | 0.000 | 0.18 ± 0.75 | 0.473 |
| HOMR-IR | 4.03 ± 0.31 | 3.07 ± 0.27 | 0.000 | 4.06 ± 0.33 | 3.94 ± 0.25 | 0.010 | −0.79 ± 0.49 | 0.000 |
| TG (mmol/L) | 1.85 ± 0.47 | 1.58 ± 0.51 | 0.004 | 1.89 ± 0.40 | 1.86 ± 0.38 | 0.220 | −0.28 ± 0.31 | 0.028 |
| LDL (mmol/L) | 2.79 ± 0.32 | 2.77 ± 0.28 | 0.174 | 2.67 ± 0.49 | 2.61 ± 0.34 | 0.301 | 0.15 ± 0.51 | 0.172 |
| HDL (mmol/L) | 0.96 ± 0.13 | 1.06 ± 0.12 | 0.001 | 0.95 ± 0.14 | 0.96 ± 0.13 | 0.084 | 0.09 ± 0.14 | 0.036 |
| SBP (mmHg) | 151.22 ± 5.95 | 146.11 ± 6.45 | 0.000 | 152.56 ± 7.25 | 150.25 ± 7.38 | 0.725 | −6.11 ± 6.63 | 0.012 |
| DBP (mmHg) | 92.44 ± 7.62 | 86.33 ± 7.17 | 0.000 | 93.16 ± 6.23 | 92.12 ± 7.16 | 0.907 | −5.88 ± 8.56 | 0.019 |
| AHI (events/h) | 37.45 ± 6.04 | 26.72 ± 4.69 | 0.000 | 38.11 ± 6.27 | 36.1 ± 4.50 | 0.265 | −10.17 ± 6.96 | 0.000 |
| LSp O2 (%) | 84.06 ± 14.58 | 87.16 ± 13.56 | 0.004 | 83.72 ± 13.77 | 84.12 ± 13.83 | 0.479 | 3.00 ± 4.46 | 0.020 |
| ESSscore | 11.83 ± 3.76 | 9.05 ± 2.75 | 0.001 | 12.50 ± 3.79 | 12.11 ± 3.16 | 0.422 | −1.78 ± 2.16 | 0.004 |
TG triglyceride, LDL low density lipoprotein cholesterol, HDL high density lipoprotein cholesterol, SBP systolic pressure, DBP diastolic pressure